天津乐敦

Tianjin Rohto Herbal Medicine Co., Ltd. is a Sino-Japanese joint venture established in 2010 by Rohto Pharmaceutical Co., Ltd., Uchida Wakanyaku, and Tianjin Lisheng Pharmaceutical Co., Ltd. Headquartered in Tianjin, China, the company specializes in the research, development, automation-driven manufacturing, and export of traditional Chinese medicine extracts, botanical extracts, and health foods. Its manufacturing facilities are designed to strictly comply with Japanese GMP standards, primarily supplying high-quality raw materials to Japan for Kampo medicine production. Beyond raw material supply, the company has expanded into proprietary drug development, acquiring and advancing its lead candidate, Kangminzhenke Granules (抗敏镇咳颗粒), into Phase 2 clinical trials for cough variant asthma. Tianjin Rohto Herbal Medicine leverages its automated extraction technologies and international quality standards to bridge traditional herbal medicine with modern pharmaceutical requirements.